Presentations focused on latest learnings and expectations for treatment of RDH12-associated retinal degenerations, and on how lessons from the licensed ocular gene therapy, voretigene neparvovec-rzyl (LUXTURNA) and from recent IRD clinical studies may be translated to RDH12. The gene discussed is RDH12; the disease is retinal degeneration.